Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Judge rejects MSN motion to add more patents to Exelixis Cabometyx patent suit
08:48pm, Friday, 25'th Feb 2022 Seeking Alpha
A federal court judge in Delaware has denied a motion from MSN Labs to add three additional patents to an existing case against Exelixis (EXEL) regarding Cabometyx.
3 Surefire Stocks to Buy Hand Over Fist During the Stock Market Sell-Off
10:06am, Friday, 25'th Feb 2022 The Motley Fool
A plunging market is the perfect opportunity to pile into these diverse, high-quality stocks.
3 Surefire Stocks to Buy Hand Over Fist During the Stock Market Sell-Off
05:06am, Friday, 25'th Feb 2022
A plunging market is the perfect opportunity to pile into these diverse, high-quality stocks.
Exelixis: The 'Rinse, Wash, And Repeat' Trade
10:56pm, Sunday, 20'th Feb 2022
Today, we revisit the mid-cap oncology name Exelixis after the company just posted better than expected quarterly results.
Exelixis beats on top and bottom lines, and analysts like what they see (EXEL)
06:29pm, Friday, 18'th Feb 2022 Seeking Alpha
Exelixis Q4 2021 results beat on the top and bottom lines after the closing bell Thursday, and Street firms are responding positively.
Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong
05:44pm, Friday, 18'th Feb 2022 Zacks Investment Research
Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.
Exelixis (EXEL) Q4 2021 Earnings Call Transcript
09:00am, Friday, 18'th Feb 2022 The Motley Fool
EXEL earnings call for the period ending December 31, 2021.
Exelixis (EXEL) Q4 2021 Earnings Call Transcript
09:00am, Friday, 18'th Feb 2022 The Motley Fool
EXEL earnings call for the period ending December 31, 2021.
Exelixis, Inc. 2021 Q4 - Results - Earnings Call Presentation
05:49am, Friday, 18'th Feb 2022 Seeking Alpha
The following slide deck was published by Exelixis, Inc.
Exelixis, Inc. 2021 Q4 - Results - Earnings Call Presentation
05:49am, Friday, 18'th Feb 2022 Seeking Alpha
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q4 2021 Results - Earnings Call Transcript
11:59pm, Thursday, 17'th Feb 2022 Seeking Alpha
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
10:15pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exelixis Non-GAAP EPS of $0.35 beats by $0.19, revenue of $451.14M beats by $94.19M
09:09pm, Thursday, 17'th Feb 2022 Seeking Alpha
Exelixis press release (EXEL): Q4 Non-GAAP EPS of $0.35 beats by $0.19.Revenue of $451.14M (+67.0% Y/Y) beats by $94.19M.Shares +2.67%.Cabozantinib franchise achieved a…
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
09:05pm, Thursday, 17'th Feb 2022 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “The Exelixis team made significant progress across our entire business in the fourth quarter and throughout 2021,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “With strong p
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q4 2021 Results - Earnings Call Transcript
06:59pm, Thursday, 17'th Feb 2022
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q4 2021 Results - Earnings Call Transcript
